Clinical Utility of Ivosidenib in the Treatment of IDH1|Mutant ...

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant ...

Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved for patients with IDH1 mutation and acute myeloid leukemia ...

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant ...

Abstract. Ivosidenib is an isocitrate dehydrogenase 1 (IDH1) inhibitor that is FDA approved for patients with IDH1 mutation and acute myeloid leukemia and ...

(PDF) Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant ...

Ivosidenib therapy resulted in long-term disease control with PFS of 20 and 13 months and duration of treatment of 26 and 13 months, ...

Ivosidenib Plus Chemotherapy to Treat AML with IDH1 Mutation - NCI

The drug was approved for use alone in people age 75 or older or for those with other health conditions that would prevent them from receiving ...

Ivosidenib in the treatment of patients with IDH1 mutated ...

The use of ivosidenib in patients with CCA and the IDH1 gene mutation after failure of previous therapy was evaluated in a phase III ClarIDHy study.

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) — and azacitidine showed encouraging clinical ...

Final Overall Survival Efficacy Results of Ivosidenib for Patients With ...

Findings In this phase 3 randomized clinical trial including 187 previously treated patients with advanced cholangiocarcinoma with IDH1 mutation ...

Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid ...

Mutations in isocitrate dehydrogenase-1 (IDH1) are recurrent in several malignancies and prevalent in acute myeloid leukemia (AML).

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in ...

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia ( ...

Clinical Trials Using Ivosidenib - NCI

Ivosidenib is in a class of medications called isocitrate dehydrogenase-1 (IDH1) inhibitors. It works by slowing or stopping the growth of cancer cells.

Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment ...

Ivosidenib is a specific and potent inhibitor of the altered IDH1 enzyme. In clinical trials, it led to impressive rates of marrow response and composite ...

Ivosidenib induces deep durable remissions in patients with newly ...

Ivosidenib is a specific inhibitor of the mutant IDH1 enzyme that drives a subset of acute myeloid leukemias. This Plenary Paper is the ...

Management of isocitrate dehydrogenase 1/2 mutated acute ...

Notably, clinical outcomes with ivosidenib were associated with molecular responses. The IDH1 mutation variant allele frequency (VAF) decreased ...

Ivosidenib - an overview | ScienceDirect Topics

Other IDH-targeting drugs have also been approved for clinical use. Olutasidenib is a potent oral selective inhibitor of mutant IDH1 approved by the FDA in 2022 ...

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or ...

Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML). Ivosidenib ...

FDA approves ivosidenib as first-line treatment for AML with IDH1 ...

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute ...

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

In a perioperative clinical trial (ClinicalTrials.gov identifier: NCT03343197), we recently observed that ivosidenib (at 500 mg once per day ...

3253 Ivosidenib for Patients with Clonal Cytopenia of Undetermined ...

Since CCUS is characterized by a lower mutation burden compared to AML or MDS, we hypothesize that the use of ivosidenib in IDH1-mutant CCUS will result in a ...

FDA Approval Summary: Ivosidenib for Relapsed or Refractory ...

In an ex vivo assay with primary human AML blasts harboring the IDH1 R132C mutation, treatment with ivosidenib for up to 7 days reduced 2-HG levels by 98% ...

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation ...

The very low incidence of grade (G) 3–4 adverse events (AEs) and treatment discontinuation due to toxicity, associated with a significantly less marked decline ...